当前位置： SCI文献检索 > BREAST CANCER RESEARCH期刊下所有文献 > MiR-7 reduces the BCSC subset by inhibiting XIST to modulate the miR-92b/Slug/ESA axis and inhibit tumor growth.

MiR-7 reduces the BCSC subset by inhibiting XIST to modulate the miR-92b/Slug/ESA axis and inhibit tumor growth.

Abstract：

BACKGROUND:Breast cancer stem cells (BCSCs) are typically seed cells of breast tumor that initiate and maintain tumor growth. MiR-7, as a cancer inhibitor, decreases the BCSC subset and inhibits tumor progression through mechanisms that remain unknown. METHODS:We examined miR-7 expression in breast cancer and developed a BCSC-driven xenograft mouse model, to evaluate the effects of miR-7 overexpression on the decrease of the BCSC subset in vitro and in vivo. In addition, we determined how miR-7 decreased the BCSC subset by using the ALDEFLUOR, lentivirus infection, dual-luciferase reporter, and chromatin immunoprecipitation-PCR assays. RESULTS:MiR-7 was expressed at low levels in breast cancer tissues compared with normal tissues, and overexpression of miR-7 directly inhibited lncRNA XIST, which mediates the transcriptional silencing of genes on the X chromosome, and reduced epithelium-specific antigen (ESA) expression by increasing miR-92b and inhibiting slug. Moreover, miR-7 suppressed CD44 and ESA by directly inhibiting the NF-κB subunit RELA and slug in breast cancer cell lines and in BCSC-driven xenografts, which confirmed the antitumor activity in mice injected with miR-7 agomir or stably infected with lenti-miR-7. CONCLUSIONS:The findings from this study uncover the molecular mechanisms by which miR-7 inhibits XIST, modulates the miR-92b/Slug/ESA axis, and decreases the RELA and CD44 expression, resulting in a reduced BCSC subset and breast cancer growth inhibition. These findings suggest a potentially targeted treatment approach to breast cancer.

journal_name

Breast Cancer Res

journal_title

Breast cancer research : BCR

authors

Li M,Pan M,You C,Zhao F,Wu D,Guo M,Xu H,Shi F,Zheng D,Dou J

doi

10.1186/s13058-020-01264-z

subject

Has Abstract

pub_date

2020-03-06 00:00:00

pages

26

issue

1

eissn

1465-5411

issn

1465-542X

pii

10.1186/s13058-020-01264-z

journal_volume

22

pub_type

杂志文章

相关文献

BREAST CANCER RESEARCH文献大全
  • Common ataxia telangiectasia mutated haplotypes and risk of breast cancer: a nested case-control study.

    abstract：INTRODUCTION:The ataxia telangiectasia mutated (ATM) gene is a tumor suppressor gene with functions in cell cycle arrest, apoptosis, and repair of DNA double-strand breaks. Based on family studies, women heterozygous for mutations in the ATM gene are reported to have a fourfold to fivefold increased risk of breast canc...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr809

    authors： Tamimi RM,Hankinson SE,Spiegelman D,Kraft P,Colditz GA,Hunter DJ

    更新日期：2004-01-01 00:00:00

  • High-throughput genomic technology in research and clinical management of breast cancer. Molecular signatures of progression from benign epithelium to metastatic breast cancer.

    abstract：:It is generally accepted that early detection of breast cancer has great impact on patient survival, emphasizing the importance of early diagnosis. In a widely recognized model of breast cancer development, tumor cells progress through chronological and well defined stages. However, the molecular basis of disease prog...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章,评审

    doi：10.1186/bcr1528

    authors： Rennstam K,Hedenfalk I

    更新日期：2006-01-01 00:00:00

  • Receptor-interacting protein kinase 2 promotes triple-negative breast cancer cell migration and invasion via activation of nuclear factor-kappaB and c-Jun N-terminal kinase pathways.

    abstract：INTRODUCTION:Metastasis is the main cause of breast cancer morbidity and mortality. Processes that allow for tumor cell migration and invasion are important therapeutic targets. Here we demonstrate that receptor-interacting protein kinase 2 (RIP2), a kinase known to be involved in inflammatory processes, also has novel...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr3629

    authors： Singel SM,Batten K,Cornelius C,Jia G,Fasciani G,Barron SL,Wright WE,Shay JW

    更新日期：2014-03-19 00:00:00

  • Rack1 mediates tyrosine phosphorylation of Anxa2 by Src and promotes invasion and metastasis in drug-resistant breast cancer cells.

    abstract：BACKGROUND:Acquirement of resistance is always associated with a highly aggressive phenotype of tumor cells. Recent studies have revealed that Annexin A2 (Anxa2) is a key protein that links drug resistance and cancer metastasis. A high level of Anxa2 in cancer tissues is correlated to a highly aggressive phenotype. Inc...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-019-1147-7

    authors： Fan Y,Si W,Ji W,Wang Z,Gao Z,Tian R,Song W,Zhang H,Niu R,Zhang F

    更新日期：2019-05-22 00:00:00

  • Expression genomics in breast cancer research: microarrays at the crossroads of biology and medicine.

    abstract：:Genome-wide expression microarray studies have revealed that the biological and clinical heterogeneity of breast cancer can be partly explained by information embedded within a complex but ordered transcriptional architecture. Comprising this architecture are gene expression networks, or signatures, reflecting biochem...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章,评审

    doi：10.1186/bcr1662

    authors： Miller LD,Liu ET

    更新日期：2007-01-01 00:00:00

  • Hypoxia and oxidative stress in breast cancer. Hypoxia signalling pathways.

    abstract：:Hypoxia-inducible factor-1 (HIF), which is centrally involved in physiological oxygen homeostasis, is also activated in the majority of tumours. Activation of HIF can occur through genetic mechanisms or as a result of hypoxia within the tumour microenvironment. In some cases HIF activation appears to be intimately lin...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章,评审

    doi：10.1186/bcr313

    authors： Pugh CW,Gleadle J,Maxwell PH

    更新日期：2001-01-01 00:00:00

  • Nighttime eating and breast cancer among Chinese women in Hong Kong.

    abstract：BACKGROUND:A novel line of research suggests that eating at nighttime may have several metabolic consequences that are highly relevant to breast cancer. We investigated the association between nighttime eating habits after 10 p.m. and breast cancer in Hong Kong women. METHODS:A hospital-based case-control study was co...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-017-0821-x

    authors： Li M,Tse LA,Chan WC,Kwok CH,Leung SL,Wu C,Yu WC,Lee PM,Tsang KH,Law SH,Vermeulen R,Gu F,Caporaso NE,Yu IT,Wang F,Yang XR

    更新日期：2017-03-17 00:00:00

  • Common genetic variation in IGF1, IGFBP-1, and IGFBP-3 in relation to mammographic density: a cross-sectional study.

    abstract：INTRODUCTION:Mammographic density is one of the strongest risk factors for breast cancer and is believed to represent epithelial and stromal proliferation. Because of the high heritability of breast density, and the role of the insulin-like growth factor (IGF) pathway in cellular proliferation and breast development, w...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr1655

    authors： Tamimi RM,Cox DG,Kraft P,Pollak MN,Haiman CA,Cheng I,Freedman ML,Hankinson SE,Hunter DJ,Colditz GA

    更新日期：2007-01-01 00:00:00

  • Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential.

    abstract：INTRODUCTION:Triple-negative breast cancer (TNBC) is a subtype of highly malignant breast cancer with poor prognosis. TNBC is not amenable to endocrine therapy and often exhibit resistance to current chemotherapeutic agents, therefore, further understanding of the biological properties of these cancer cells and develop...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-014-0434-6

    authors： Pelicano H,Zhang W,Liu J,Hammoudi N,Dai J,Xu RH,Pusztai L,Huang P

    更新日期：2014-09-11 00:00:00

  • Nitric oxide deficiency and endothelial-mesenchymal transition of pulmonary endothelium in the progression of 4T1 metastatic breast cancer in mice.

    abstract：BACKGROUND:Mesenchymal transformation of pulmonary endothelial cells contributes to the formation of a metastatic microenvironment, but it is not known whether this precedes or follows early metastasis formation. In the present work, we characterize the development of nitric oxide (NO) deficiency and markers of endothe...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-018-1013-z

    authors： Smeda M,Kieronska A,Adamski MG,Proniewski B,Sternak M,Mohaissen T,Przyborowski K,Derszniak K,Kaczor D,Stojak M,Buczek E,Jasztal A,Wietrzyk J,Chlopicki S

    更新日期：2018-08-03 00:00:00

  • The effect of psychosocial factors on breast cancer outcome: a systematic review.

    abstract：INTRODUCTION:We sought to review the available evidence regarding the effect of psychosocial factors on the survival of breast cancer patients. METHODS:We systematically searched the PubMed and PsycINFO databases to identify relevant studies. RESULTS:We identified 31 studies examining the association of various psych...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章,meta分析

    doi：10.1186/bcr1744

    authors： Falagas ME,Zarkadoulia EA,Ioannidou EN,Peppas G,Christodoulou C,Rafailidis PI

    更新日期：2007-01-01 00:00:00

  • Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients.

    abstract：INTRODUCTION:The HER (human EGFR related) family of receptor tyrosine kinases (HER1/EGFR (epidermal growth factor receptor)/c-erbB1, HER2/c-erbB2, HER3/c-erbB3 and HER4/c-erbB4) shares a high degree of structural and functional homology. It constitutes a complex network, coupling various extracellular ligands to intrac...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr1843

    authors： Sassen A,Rochon J,Wild P,Hartmann A,Hofstaedter F,Schwarz S,Brockhoff G

    更新日期：2008-01-01 00:00:00

  • Combined the SMAC mimetic and BCL2 inhibitor sensitizes neoadjuvant chemotherapy by targeting necrosome complexes in tyrosine aminoacyl-tRNA synthase-positive breast cancer.

    abstract：BACKGROUND:Chemotherapy is the standard treatment for breast cancer; however, the response to chemotherapy is disappointingly low. Here, we investigated the alternative therapeutic efficacy of novel combination treatment with necroptosis-inducing small molecules to overcome chemotherapeutic resistance in tyrosine amino...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-020-01367-7

    authors： Lee KM,Lee H,Han D,Moon WK,Kim K,Oh HJ,Choi J,Hwang EH,Kang SE,Im SA,Lee KH,Ryu HS

    更新日期：2020-11-25 00:00:00

  • Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism.

    abstract：INTRODUCTION:Human epidermal growth factor 2 (Her2), a receptor tyrosine kinase, is overexpressed in breast cancers. It has been successfully targeted by small molecule kinase inhibitors and by antibodies. Recent clinical data show a synergistic response in patients when two antibodies, trastuzumab and pertuzumab, are ...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr2888

    authors： Fuentes G,Scaltriti M,Baselga J,Verma CS

    更新日期：2011-05-22 00:00:00

  • FAK activates AKT-mTOR signaling to promote the growth and progression of MMTV-Wnt1-driven basal-like mammary tumors.

    abstract：BACKGROUND:Breast cancer is a heterogeneous disease. Hence, stratification of patients based on the subtype of breast cancer is key to its successful treatment. Among all the breast cancer subtypes, basal-like breast cancer is the most aggressive subtype with limited treatment options. Interestingly, we found focal adh...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-020-01298-3

    authors： Paul R,Luo M,Mo X,Lu J,Yeo SK,Guan JL

    更新日期：2020-06-03 00:00:00

  • Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial.

    abstract：INTRODUCTION:Pre-clinical data suggest p53-dependent anthracycline-induced apoptosis and p53-independent taxane activity. However, dedicated clinical research has not defined a predictive role for TP53 gene mutations. The aim of the current study was to retrospectively explore the prognosis and predictive values of TP5...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章,随机对照试验

    doi：10.1186/bcr3179

    authors： Fernández-Cuesta L,Oakman C,Falagan-Lotsch P,Smoth KS,Quinaux E,Buyse M,Dolci MS,Azambuja ED,Hainaut P,Dell'orto P,Larsimont D,Francis PA,Crown J,Piccart-Gebhart M,Viale G,Leo AD,Olivier M

    更新日期：2012-05-02 00:00:00

  • Inducible transgenics. New lessons on events governing the induction and commitment in mammary tumorigenesis.

    abstract：:Breast cancer arises from multiple genetic events that together contribute to the established, irreversible malignant phenotype. The development of inducible tissue-specific transgenics has allowed a careful dissection of the events required for induction and subsequent maintenance of tumorigenesis. Mammary gland targ...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr297

    authors： Hulit J,Di Vizio D,Pestell RG

    更新日期：2001-01-01 00:00:00

  • Laminin isoform expression in breast tumors.

    abstract：:Certain laminins of vascular basement membranes have been identified in human breast tumors and brain gliomas that share the same beta1 chain. These laminins are new carcinoma angiogenic markers and might represent potential targets for antiangiogenic therapy. ...

    journal_title：Breast cancer research : BCR

    pub_type： 评论,杂志文章

    doi：10.1186/bcr1270

    authors： Holler E

    更新日期：2005-01-01 00:00:00

  • Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study.

    abstract：INTRODUCTION:Before any new methodology can be introduced into the routine diagnostic setting it must be technically validated against the established standards. To this end, a ring study involving five international pathology laboratories was initiated to validate chromogenic in situ hybridisation (CISH) against fluor...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章,多中心研究

    doi：10.1186/bcr1776

    authors： van de Vijver M,Bilous M,Hanna W,Hofmann M,Kristel P,Penault-Llorca F,Rüschoff J

    更新日期：2007-01-01 00:00:00

  • The AIB1 glutamine repeat polymorphism is not associated with risk of breast cancer before age 40 years in Australian women.

    abstract：INTRODUCTION:AIB1, located at 20q12, is a member of the steroid hormone coactivator family. It contains a glutamine repeat (CAG/CAA) polymorphism at its carboxyl-terminal region that may alter the transcriptional activation of the receptor and affect susceptibility to breast cancer through altered sensitivity to hormon...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr1009

    authors： Montgomery KG,Chang JH,Gertig DM,Dite GS,McCredie MR,Giles GG,Southey MC,Hopper JL,Campbell IG

    更新日期：2005-01-01 00:00:00

  • Identification of chemokine receptors as potential modulators of endocrine resistance in oestrogen receptor-positive breast cancers.

    abstract：INTRODUCTION:Endocrine therapies target oestrogenic stimulation of breast cancer (BC) growth, but resistance remains problematic. Our aims in this study were (1) to identify genes most strongly associated with resistance to endocrine therapy by intersecting global gene transcription data from patients treated presurgic...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-014-0447-1

    authors： Ribas R,Ghazoui Z,Gao Q,Pancholi S,Rani A,Dunbier A,Dowsett M,Martin LA

    更新日期：2014-10-31 00:00:00

  • Raised mammographic density: causative mechanisms and biological consequences.

    abstract：:High mammographic density is the most important risk factor for breast cancer, after ageing. However, the composition, architecture, and mechanical properties of high X-ray density soft tissues, and the causative mechanisms resulting in different mammographic densities, are not well described. Moreover, it is not know...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章,评审

    doi：10.1186/s13058-016-0701-9

    authors： Sherratt MJ,McConnell JC,Streuli CH

    更新日期：2016-05-03 00:00:00

  • Profiling gene promoter occupancy of Sox2 in two phenotypically distinct breast cancer cell subsets using chromatin immunoprecipitation and genome-wide promoter microarrays.

    abstract：INTRODUCTION:Aberrant expression of the embryonic stem cell marker Sox2 has been reported in breast cancer (BC). We previously identified two phenotypically distinct BC cell subsets separated based on their differential response to a Sox2 transcription activity reporter, namely the reporter-unresponsive (RU) and the mo...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-014-0470-2

    authors： Jung K,Wang P,Gupta N,Gopal K,Wu F,Ye X,Alshareef A,Bigras G,McMullen TP,Abdulkarim BS,Lai R

    更新日期：2014-11-08 00:00:00

  • Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy.

    abstract：INTRODUCTION:Reliable predictive and prognostic markers for routine diagnostic purposes are needed for breast cancer patients treated with neoadjuvant chemotherapy. We evaluated protein biomarkers in a cohort of 116 participants of the GeparDuo study on anthracycline/taxane-based neoadjuvant chemotherapy for operable b...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1186/bcr2363

    authors： Darb-Esfahani S,Loibl S,Müller BM,Roller M,Denkert C,Komor M,Schlüns K,Blohmer JU,Budczies J,Gerber B,Noske A,du Bois A,Weichert W,Jackisch C,Dietel M,Richter K,Kaufmann M,von Minckwitz G

    更新日期：2009-01-01 00:00:00

  • Finding the needle in the haystack: why high-throughput screening is good for your health.

    abstract：:High-throughput screening is an essential component of the toolbox of modern technologies that improve speed and efficiency in contemporary cancer drug development. This is particularly important as we seek to exploit, for maximum therapeutic benefit, the large number of new molecular targets emerging from the Human G...

    journal_title：Breast cancer research : BCR

    pub_type： 社论

    doi：10.1186/bcr440

    authors： Aherne GW,McDonald E,Workman P

    更新日期：2002-01-01 00:00:00

  • Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients.

    abstract：BACKGROUND:Controversies exist as to whether the genetic polymorphisms of the enzymes responsible for the metabolism of tamoxifen can predict breast cancer outcome in patients using adjuvant tamoxifen. Direct measurement of concentrations of active tamoxifen metabolites in serum may be a more biological plausible and r...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-017-0916-4

    authors： Helland T,Henne N,Bifulco E,Naume B,Borgen E,Kristensen VN,Kvaløy JT,Lash TL,Alnæs GIG,van Schaik RH,Janssen EAM,Hustad S,Lien EA,Mellgren G,Søiland H

    更新日期：2017-11-28 00:00:00

  • Inflammation markers and cognitive performance in breast cancer survivors 20 years after completion of chemotherapy: a cohort study.

    abstract：BACKGROUND:Inflammation is an important candidate mechanism underlying cancer and cancer treatment-related cognitive impairment. We investigated levels of blood cell-based inflammatory markers in breast cancer survivors on average 20 years after chemotherapy and explored the relation between these markers and global co...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-018-1062-3

    authors： van der Willik KD,Koppelmans V,Hauptmann M,Compter A,Ikram MA,Schagen SB

    更新日期：2018-11-15 00:00:00

  • Functional variants at the 21q22.3 locus involved in breast cancer progression identified by screening of genome-wide estrogen response elements.

    abstract：INTRODUCTION:Estrogen forms a complex with the estrogen receptor (ER) that binds to estrogen response elements (EREs) in the regulatory region of estrogen-responsive genes and regulates their transcription. Sequence variants in the regulatory regions have the potential to affect the transcription factor-regulatory sequ...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-014-0455-1

    authors： Hsiung CN,Chu HW,Huang YL,Chou WC,Hu LY,Hsu HM,Wu PE,Hou MF,Yu JC,Shen CY

    更新日期：2014-10-09 00:00:00

  • GATA3 protein as a MUC1 transcriptional regulator in breast cancer cells.

    abstract：INTRODUCTION:Recent studies have demonstrated that members of the GATA-binding protein (GATA) family (GATA4 and GATA5) might have pivotal roles in the transcriptional upregulation of mucin genes (MUC2, MUC3 and MUC4) in gastrointestinal epithelium. The zinc-finger GATA3 transcription factor has been reported to be invo...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr1617

    authors： Abba MC,Nunez MI,Colussi AG,Croce MV,Segal-Eiras A,Aldaz CM

    更新日期：2006-01-01 00:00:00

  • Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers.

    abstract：INTRODUCTION:The majority of breast cancers that occur in BRCA1 mutation carriers (BRCA1 carriers) are estrogen receptor-negative (ER-). Therefore, it has been suggested that ER negativity is intrinsic to BRCA1 cancers and reflects the cell of origin of these tumors. However, approximately 20% of breast cancers that de...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr2776

    authors： Tung N,Miron A,Schnitt SJ,Gautam S,Fetten K,Kaplan J,Yassin Y,Buraimoh A,Kim JY,Szász AM,Tian R,Wang ZC,Collins LC,Brock J,Krag K,Legare RD,Sgroi D,Ryan PD,Silver DP,Garber JE,Richardson AL

    更新日期：2010-01-01 00:00:00